RU2754664C2 - 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета - Google Patents
6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета Download PDFInfo
- Publication number
- RU2754664C2 RU2754664C2 RU2018131775A RU2018131775A RU2754664C2 RU 2754664 C2 RU2754664 C2 RU 2754664C2 RU 2018131775 A RU2018131775 A RU 2018131775A RU 2018131775 A RU2018131775 A RU 2018131775A RU 2754664 C2 RU2754664 C2 RU 2754664C2
- Authority
- RU
- Russia
- Prior art keywords
- pyridin
- phenyl
- methylmorpholin
- methyl
- compound according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16156530.4 | 2016-02-19 | ||
| EP16156530 | 2016-02-19 | ||
| PCT/EP2017/053612 WO2017140841A1 (en) | 2016-02-19 | 2017-02-17 | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018131775A RU2018131775A (ru) | 2020-03-20 |
| RU2018131775A3 RU2018131775A3 (enExample) | 2020-04-08 |
| RU2754664C2 true RU2754664C2 (ru) | 2021-09-06 |
Family
ID=55404645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018131775A RU2754664C2 (ru) | 2016-02-19 | 2017-02-17 | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11077113B2 (enExample) |
| EP (1) | EP3416945B1 (enExample) |
| JP (3) | JP6997462B2 (enExample) |
| CN (3) | CN113754581A (enExample) |
| AU (3) | AU2017219846B2 (enExample) |
| CY (1) | CY1123285T1 (enExample) |
| DK (1) | DK3416945T3 (enExample) |
| ES (1) | ES2816376T3 (enExample) |
| HR (1) | HRP20201400T1 (enExample) |
| HU (1) | HUE050863T2 (enExample) |
| LT (1) | LT3416945T (enExample) |
| PL (1) | PL3416945T3 (enExample) |
| PT (1) | PT3416945T (enExample) |
| RS (1) | RS60898B1 (enExample) |
| RU (1) | RU2754664C2 (enExample) |
| SI (1) | SI3416945T1 (enExample) |
| SM (1) | SMT202000523T1 (enExample) |
| TW (1) | TWI721104B (enExample) |
| WO (1) | WO2017140841A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3416945T3 (pl) * | 2016-02-19 | 2020-12-28 | Sprint Bioscience Ab | Związki 6-arylo-4-(morfolin-4-ylo)-1h-pirydyn-2-onu przydatne w leczeniu nowotworu i cukrzycy |
| PT3416957T (pt) * | 2016-02-19 | 2020-09-25 | Sprint Bioscience Ab | Compostos 6-heterociclil-4-morfolin-4-ilpiridin-2-ona úteis para o tratamento do cancro e da diabetes |
| HRP20220497T1 (hr) * | 2017-08-23 | 2022-05-27 | Sprint Bioscience Ab | Spoj morfolinilpiridona |
| IL302356A (en) * | 2017-08-23 | 2023-06-01 | Sprint Bioscience Ab | Pyridylpyridone compounds |
| PL3672948T3 (pl) * | 2017-08-23 | 2022-12-05 | Sprint Bioscience Ab | Związki pirydynoamino-pirydonu i pirymidynoamino-pirydonu |
| IL302355A (en) | 2017-08-23 | 2023-06-01 | Sprint Bioscience Ab | Azaindolylpyridone and diazaindolylpyridone compounds |
| WO2020008046A1 (en) | 2018-07-06 | 2020-01-09 | Sprint Bioscience Ab | Biomarker |
| US12540115B2 (en) * | 2019-08-21 | 2026-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of phospholipid synthesis and methods of use |
| JP2023550638A (ja) | 2020-11-25 | 2023-12-04 | デシフェラ・ファーマシューティカルズ，エルエルシー | ウイルス感染症の処置に使用するための、ｖｓｐ３４阻害剤としてのモルホリノ誘導体 |
| WO2022115549A1 (en) | 2020-11-25 | 2022-06-02 | Deciphera Pharmaceuticals, Llc | Anti-viral activity of vps34 inhibitors |
| CN117083064A (zh) | 2020-11-25 | 2023-11-17 | 德西费拉制药有限责任公司 | 作为vps34抑制剂用于治疗病毒感染的吡啶基吡啶酮衍生物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA013811B1 (ru) * | 2002-11-21 | 2010-08-30 | Новартис Вэксинес Энд Дайэгностикс, Инк. | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака |
| WO2013190510A2 (en) * | 2012-06-22 | 2013-12-27 | Sanofi | NOVEL 2,3-DIHYDRO-1H-IMIDAZO{1,2-a}PYRIMIDIN-5-ONE and this1,2,3,4-TETRAHYDROPYRIMIDO{1,2-a}PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF |
| RU2537945C2 (ru) * | 2008-11-10 | 2015-01-10 | Юниверсити Оф Базель | Триазиновые, пиримидиновые и пиридиновые аналоги и их применение в качестве терапевтических агентов и диагностических проб |
| WO2015030057A1 (ja) * | 2013-08-29 | 2015-03-05 | 富士フイルム株式会社 | 新規なモルホリン誘導体またはその塩 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2448940T3 (pl) | 2009-07-02 | 2014-10-31 | Sanofi Sa | Pochodne 6,7,8,9-tetrahydro-pirymido{1,2-a} pirymidyn-4-onu, ich wytwarzanie i zastosowanie farmaceutyczne |
| EA201390917A1 (ru) * | 2010-12-21 | 2013-12-30 | Новартис Аг | Дигетероарильные соединения в качестве ингибиторов vps34 |
| PT2655375E (pt) * | 2010-12-23 | 2015-03-02 | Sanofi Sa | Derivados de pirimidinona, sua preparação e sua utilização farmacêutica |
| GB201120317D0 (en) | 2011-11-24 | 2012-01-04 | Queen Mary & Westfield College | Screening method |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| WO2014145512A2 (en) * | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Potent small molecule inhibitors of autophagy, and methods of use thereof |
| TN2016000270A1 (en) | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
| MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
| JP2017528486A (ja) * | 2014-09-17 | 2017-09-28 | ヴァーセオン コーポレイション | セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物 |
| PL3416945T3 (pl) * | 2016-02-19 | 2020-12-28 | Sprint Bioscience Ab | Związki 6-arylo-4-(morfolin-4-ylo)-1h-pirydyn-2-onu przydatne w leczeniu nowotworu i cukrzycy |
-
2017
- 2017-02-17 PL PL17705878T patent/PL3416945T3/pl unknown
- 2017-02-17 SI SI201730395T patent/SI3416945T1/sl unknown
- 2017-02-17 US US15/999,530 patent/US11077113B2/en active Active
- 2017-02-17 TW TW106105179A patent/TWI721104B/zh not_active IP Right Cessation
- 2017-02-17 EP EP17705878.1A patent/EP3416945B1/en active Active
- 2017-02-17 HU HUE17705878A patent/HUE050863T2/hu unknown
- 2017-02-17 AU AU2017219846A patent/AU2017219846B2/en active Active
- 2017-02-17 WO PCT/EP2017/053612 patent/WO2017140841A1/en not_active Ceased
- 2017-02-17 DK DK17705878.1T patent/DK3416945T3/da active
- 2017-02-17 LT LTEP17705878.1T patent/LT3416945T/lt unknown
- 2017-02-17 CN CN202111121825.5A patent/CN113754581A/zh active Pending
- 2017-02-17 CN CN202111123598.XA patent/CN113845472A/zh active Pending
- 2017-02-17 JP JP2018562701A patent/JP6997462B2/ja active Active
- 2017-02-17 RU RU2018131775A patent/RU2754664C2/ru active
- 2017-02-17 HR HRP20201400TT patent/HRP20201400T1/hr unknown
- 2017-02-17 PT PT177058781T patent/PT3416945T/pt unknown
- 2017-02-17 CN CN201780013738.3A patent/CN108698996B/zh active Active
- 2017-02-17 RS RS20201057A patent/RS60898B1/sr unknown
- 2017-02-17 ES ES17705878T patent/ES2816376T3/es active Active
- 2017-02-17 SM SM20200523T patent/SMT202000523T1/it unknown
-
2020
- 2020-08-27 CY CY20201100804T patent/CY1123285T1/el unknown
-
2021
- 2021-06-29 US US17/362,763 patent/US11633403B2/en active Active
- 2021-08-12 AU AU2021215234A patent/AU2021215234B2/en not_active Ceased
- 2021-12-08 JP JP2021199161A patent/JP7389504B2/ja active Active
-
2023
- 2023-03-09 US US18/181,046 patent/US20240050439A1/en not_active Abandoned
- 2023-10-13 AU AU2023248170A patent/AU2023248170A1/en not_active Abandoned
- 2023-11-10 JP JP2023192216A patent/JP2024016225A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA013811B1 (ru) * | 2002-11-21 | 2010-08-30 | Новартис Вэксинес Энд Дайэгностикс, Инк. | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака |
| RU2537945C2 (ru) * | 2008-11-10 | 2015-01-10 | Юниверсити Оф Базель | Триазиновые, пиримидиновые и пиридиновые аналоги и их применение в качестве терапевтических агентов и диагностических проб |
| WO2013190510A2 (en) * | 2012-06-22 | 2013-12-27 | Sanofi | NOVEL 2,3-DIHYDRO-1H-IMIDAZO{1,2-a}PYRIMIDIN-5-ONE and this1,2,3,4-TETRAHYDROPYRIMIDO{1,2-a}PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF |
| WO2015030057A1 (ja) * | 2013-08-29 | 2015-03-05 | 富士フイルム株式会社 | 新規なモルホリン誘導体またはその塩 |
Non-Patent Citations (1)
| Title |
|---|
| V. AGGARWAL ET AL, Synthesis, no.3, 1982, pp. 214-216. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7389504B2 (ja) | がんおよび糖尿病の治療に有用な６－アリール－４－モルホリン－１－イルピリドン化合物 | |
| JP6858984B2 (ja) | がんおよび糖尿病の治療に有用な６−ヘテロシクリル−４−モルホリン−４−イルピリジン−２−オン化合物 | |
| KR102730753B1 (ko) | 피리딘아민-피리돈 및 피리미딘아민-피리돈 화합물 | |
| JP2023021277A (ja) | アザインドリルピリドンおよびジアザインドリルピリドン化合物 | |
| KR102730718B1 (ko) | 피리딜피리돈 화합물 | |
| TWI803511B (zh) | 嗎啉基吡啶酮化合物 | |
| CA3015045C (en) | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes | |
| RU2803158C2 (ru) | Морфолинилпиридоны | |
| RU2788659C2 (ru) | Азаиндолилпиридоны и диазаиндолилпиридоны |